AMPH Amphastar Pharmaceuticals, Inc.
$25.47▲ +1.31%
Healthcare
Other
Volume 225.2K
Avg Volume (10D) 360.6K
Key Metrics & Fundamentals
Market Cap
$1.08B
P/E Ratio
15.1
Div Yield
0.00%
52W Range
16.65 - 29.52
% vs 50 MA
4.62%
% vs 200 MA
14.30%
RSI-14
50.5
MACD Histogram
-0.2200
Beta (1Y vs SPY)
0.57
Free Cash Flow
$42.73M
Gross Rev
$183.90M
Gross Profit
$93.47M
EBITDA
$61.66M
COGS
$90.43M
Operating Exp
$53.74M
Operating Income
$39.73M
EBIT
$39.73M
Pretax Income
$38.54M
Net Income
$30.35M
EPS (Diluted)
0.67
Price & Volume History
Loading chart…
Recent News
Amphastar Pharmaceuticals (AMPH) Stock Looks About Right After A 42% Slide
Simply Wall St. · Oct 16, 2026 9:11 PM ET
1 Safe-and-Steady Stock to Research Further and 2 Facing Challenges
StockStory · Oct 8, 2026 4:08 AM ET
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Zacks · Oct 6, 2026 8:40 AM ET
3 Stocks Under $50 We Think Twice About
StockStory · Oct 1, 2026 7:57 AM ET
3 Reasons to Avoid AMPH and 1 Stock to Buy Instead
StockStory · Sep 24, 2026 11:44 AM ET
3 Russell 2000 Stocks We Find Risky
StockStory · Sep 21, 2026 6:06 AM ET
3 Small-Cap Stocks with Warning Signs
StockStory · Sep 18, 2026 5:04 PM ET
Amphastar Pharmaceuticals (NASDAQ:AMPH): Strongest Q2 Results from the Generic Pharmaceuticals Group
StockStory · Sep 17, 2026 9:06 AM ET
Amphastar Pharmaceuticals (AMPH) Rebounds In Focus, Is It Slightly Overvalued?
Simply Wall St. · Sep 6, 2026 6:13 PM ET
Amphastar Pharmaceuticals (AMPH) Stock Looks Cheap With Earnings Doing The Heavy Lifting
Simply Wall St. · Sep 5, 2026 6:11 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See AMPH's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.